ArticleRSC advances2026
Enhancing the sensitivity of nanobodies through covalent and non-covalent polymerization.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The precise identification of disease using antibodies is crucial for guiding therapeutic interventions. Among these binding proteins, the nanobody is the smallest known antigen-binding fragment. This study aimed to enhance antigen detection sensitivity by integrating covalent dimerization and non-covalent heptamerization strategies to increase the density of nanobodies for improved antigen capture. First, we synthesized a SpyTag-Catcher-fused nanobody and a heptamerization protein using a prokaryotic expression system. Western blot was used to preliminarily verify the nanobody's antigen-binding capability. Surface Plasmon Resonance (SPR) analysis revealed that the enhanced immunoactivity of the nanobody polymerization resulted from their increased affinity. Finally, we employed these nanobodies to improve the sensitivity of sandwich immunoassays, specifically immuno-magnetic beads and ELISA, for detecting antigens in solution. Our findings demonstrate that the 14-mer nanobody, formed by covalent dimers and non-covalently self-assembled heptamers, enhanced antigen capture capability by more than tenfold.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.